https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42282 Wed 16 Aug 2023 14:37:30 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33853 Wed 04 Sep 2019 10:04:12 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37462 Wed 02 Mar 2022 14:28:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31943 P = 0.0012). Comparison (2) demonstrated a moderate difference with centre 2 plans producing slightly lower rectal doses (P = 0.013). Comparison (3) further demonstrated that Rectafix returned lower mean doses than SpaceOAR (P < 0.001). Although all dose levels were in favour of Rectafix, in absolute terms differences were small (2.6-9.0%). Conclusions: In well-selected prostate SBRT patients, Rectafix and SpaceOAR RDD's provide approximately equivalent rectal sparing.]]> Wed 02 Mar 2022 14:25:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45129 Thu 27 Oct 2022 10:56:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34741 Thu 17 Feb 2022 09:29:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52300 Mon 09 Oct 2023 10:17:40 AEDT ]]>